IL-6 in pulmonary hypertension: why novel is not always best
- PMID: 32300021
- DOI: 10.1183/13993003.00314-2020
IL-6 in pulmonary hypertension: why novel is not always best
Conflict of interest statement
Conflict of interest: M. Toshner reports personal fees from GSK and Morphogen IX, grants and personal fees from J&J/Actelion, grants from Merck, Bayer and Roche, outside the submitted work. Conflict of interest: A. Rothman reports grants and personal fees from Sonivie, Novartis, Medtronic, Endotronix, Abbott and Actelion, outside the submitted work.
Comment on
-
Cellular sources of interleukin-6 and associations with clinical phenotypes and outcomes in pulmonary arterial hypertension.Eur Respir J. 2020 Apr 16;55(4):1901761. doi: 10.1183/13993003.01761-2019. Print 2020 Apr. Eur Respir J. 2020. PMID: 32029443 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical